Real-life clinical impact of a five-tiered classification of pituitary tumors.
Nicolas SahakianRomain AppayNoémie ResseguierThomas GraillonCécilia PiazzolaCécilia LaureDominique Figarella-BrangerJean RégisCastinetti FredericThierry BrueHenry DufourThomas CunyPublished in: European journal of endocrinology (2022)
This is the first study to assess, on a cohort of 607 well-characterized patients, the real-life therapeutic impact of the five-tiered clinicopathological classification of pituitary tumors. First, we validate that pituitary tumor grades predict the evolutionary risk of the tumor, with a significant higher risk of progression/recurrence in invasive and/or proliferative tumors (mean follow-up: 47 ± 30 months, median: 38 months). Moreover, our study provides evidence that patients with proliferative tumors have a higher risk to be retreated after primary surgery and point toward the fact that radiotherapy can successfully control tumor growth in case of progression or recurrence. Our findings advocate for a personalized therapeutic approach in clinically aggressive pituitary tumors.